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Abstract
Background: Many groups, including our own, have proposed the use of DNA methylation profiles as biomarkers
for various disease states. While much research has been done identifying DNA methylation signatures in cancer
vs. normal etc., we still lack sufficient knowledge of the role that differential methylation plays during normal
cellular differentiation and tissue specification. We also need thorough, genome level studies to determine the
meaning of methylation of individual CpG dinucleotides in terms of gene expression.
Results: In this study, we have used (insert statistical method here) to compile unique DNA methylation signatures
from normal human heart, lung, and kidney using the Illumina Infinium 27 K methylation arraysand compared
those to gene expression by RNA sequencing. We have identified unique signatures of global DNA methylation for
human heart, kidney and liver, and showed that DNA methylation data can be used to correctly classify various
tissues. It indicates that DNA methylation reflects tissue specificity and may play an important role in tissue
differentiation. The integrative analysis of methylation and RNA-Seq data showed that gene methylation and its
transcriptional levels were comprehensively correlated. The location of methylation markers in terms of distance to
transcription start site and CpG island showed no effects on the regulation of gene expression by DNA
methylation in normal tissues.
Conclusions: This study showed that an integrative analysis of methylation array and RNA-Seq data can be utilized
to discover the global regulation of gene expression by DNA methylation and suggests that DNA methylation
plays an important role in normal tissue differentiation via modulation of gene expression.
Background
With the exception of the transient wave of global
demethylation that occurs during embryonic develop-
ment, DNA methylation is considered, relative to cova-
lent histone modifications, to be a more permanent,
heritable mark. DNA methylation of cytosine at position
C5 in CpG dinucleotides is reported to influence specific
gene expression, especially to suppress gene expression
[1]. CpG dinucleotides are largely depleted from the
genome except for in regions referred to as CpG islands,
found in the proximal promoter regions of many genes
[2,3]. Most of these CpG clusters are unmethylated dur-
ing normal cell development, except for tissue-specific
differentially methylated genes [3], imprinted genes [4]
and some X-chromosome inactivation related genes
[5-7]. Modern genetic studies have established that
DNA methylation is required not only for embryonic
development [8], but also plays a critical role in diseased
status such as cancer [9]. As the field of epigenomics
expands to study multiple diverse normal and pathologi-
cal processes, it becomes increasingly important to
understand the role that normal global genome-wide
DNA methylation patterns play in influencing global
gene expression.
A differentiated cell in an organism is thought to con-
tain essentially the same DNA as its ancestors, but it
differs in the quality and quantity of gene expressions,
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original work is properly cited.and therefore functions differently. DNA-binding tran-
scription factors are crucial determinants of gene
expression, and many groups have shown that that epi-
genetic mechanisms such as nucleosome positioning
and covalent chromatin modifications and are involved
in regulating transcription factor accessibility and gene
expression during cellular differentiation [10].
Understanding of DNA methylation in regulating nor-
mal tissue-specific genome function is still limited,
although the causal relationship between DNA methyla-
tion and gene regulation has been well studied [10,11].
More than 150 tissue-specific differentially methylated
regions (TDMs) have been identified via a Restriction
landmark genomic scanning (RLGS) assay and expres-
sion of genes associated with these regions have been
shown to be correlated with DNA methylation [12,13].
Other studies have linked DNA methylation to tissue-
specific gene expression by studying the promoter
regions of a small number of imprinted genes and those
involved in maintenance of pluripotency [13-15]. Both
sexes use genomic imprinting to control the expression
of approximately 100 imprinted genes and allowing
monoallelic expression from either the maternal or
paternal allele, and most imprinted genes regulate pla-
cental and fetal growth [16,17]. However, studies on
small subsets of tissue specific genes in mice could not
prove an association between DNA methylation and
gene expression [18,19]. The inconsistent result may
result from a limited number of genes being studied and
differences in the CpG island content of their proximal
promoter regions.
The advent of global DNA methylation arrays and
next-generation RNA sequencing transcriptome studies
have made it possible to explore the global relationship
between gene methylation and expression during cell
development and tissue differentiation. Researchers
using a comparative genomic approach to study the
DNA methylation patterns among species have success-
fully identified a role of DNA methylation in the evolu-
tion of gene regulation across the tissues and species
[20]. The fast development of next generation sequen-
cing technology provides a comprehensive and reliable
approach, RNA-Seq, to fast quantify the global tran-
scription levels of a tissue [21]. RNA-Seq allows
researchers to count the amount of mRNA being
sequenced, and consequently, it more accurately mea-
sures the transcriptional levels than the fluorescent
intensity-based methods, such as mRNA microarray and
qPCR. In addition, RNA-Seq provides single nucleotide
resolution for mRNA, therefore, it can differentiate gene
isoforms (transcripts), whereas microarray is often not
able to identify isoforms because it uses probes to detect
mRNA levels. Methylation array and RNA-Seq techni-
ques are powerful tools to study global methylation
variation and transcription changes, but no joint analysis
with these two type data have been reported yet. In this
study, we use an integrative analysis of both data sets
across three different normal human tissues with the
intention of shedding light on understanding the under-
lying mechanism of DNA methylation mediating normal
tissue differentiation.
Results
The DNA promoter methylation data for human heart,
kidney and liver tissue samples was obtained from the
NCBI GEO database with the accession number
GSE26033 http://www.ncbi.nlm.nih.gov/projects/geo/
query/acc.cgi?acc=GSE26033. This data was generated
by Pai et al. who studied the methylation patterns
between human and chimpanzee tissues [20]. Six indivi-
dual samples were collected for each tissue type. The
methylation profiles were generated by Illumina
HumanMethylation27 DNA Analysis BeadChip that
contains 27,578 CpG loci located in either CpG islands
or non-CpG islands of promoter regions.
The DNA methylation profiles of human heart, kid-
ney, and liver were integrated with RNA-Seq data for
analysis. The RNA-Seq data were obtained from Human
BodyMap 2.0 project by Illumina, Inc. Human BodyMap
2.0 project conducted deep sequencing for total RNA of
16 individual human tissues with one sample for each
tissue type. The RNA-Seq data was available in NCBI
GEO database with accession number GSE30611 http://
www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?
acc=GSE30611. In this study, we combined RNA-Seq
data for heart, kidney and liver tissues with DNA
methylation data.
Data quantification and quality
The variability in gene methylation level has various
sources, including tissue differentiation, individual sam-
ple variation, and technical variance. For the same tis-
sue, genes are expected to carry similar epigenetic
modification to control tissue differentiation, thus the
variability between sample replicates is expected to be
marginal comparing with the variability between differ-
ent tissues. To evaluate the quality of the DNA methyla-
tion data, we plotted the methylation levels between
each pair of samples from the same tissue. All plots
consistently showed low variability. Figure 1A-C show 3
plots for random pair of samples from heart, kidney and
liver. The amount of genes that have a standard devia-
tion less than 0.1 were 98.3%, 91.1%, and 97.6% for
heart, kidney and liver, respectively. When we plot the
average methylation level for each CpG marker between
tissues, the variation was substantial larger (Figure 1D-
F). It is clear that points in 1E and 1F are more wide-
spread than that in 1D, implying difference between
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Page 2 of 11Figure 1 Data quality and variation. A-C. Plots of DNA methylation levels between a random pair of samples from the same tissues. D-F. Plots
of average DNA methylation levels between the three tissues, heart, kidney and liver. G-I. Plots of RNA-Seq expression levels between the three
tissues. J-L. QQ plots of RNA-Seq expression levels between the three tissues.
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liver or between kidney and liver. Heart and kidney
both develop from mesoderm and liver develops from
endoderm, therefore, not only do epigenetic changes
correctly differentiate between differentiated cell types,
but they also reveal the distinct embryonic origins of
tissues.
The RNA-Seq data from Illumina BodyMap 2.0 pro-
ject was generated by Illumina HiSeq 2000 with 50 bp
paired end sequencing. For each sample, ~160 million
reads were generated. We used Tophat [22] to map
short reads onto the reference sequence of human gen-
ome 19 (GRCh37/hg19). About 55% paired reads were
aligned with the reference genome. Software Cufflinks
[23] was then used to quantify the expression levels of
transcripts. We counted from 45,000 to 48,000 tran-
scripts from 3 tissues and compared the transcriptional
levels between each pair of tissues. Figure 1G-I plot the
pairwise expression levels between two tissues. The
transcriptional levels are represented at logarithm scale
for FPKM values calculated from Cufflinks. At log scale,
the expression levels are aligned well between tissues
with the majority of plots located in the lower level.
To further explore the expression patterns, we drew
quantile-quantile plots to compare the expression distri-
butions between tissues (Figure 1J-L). All data distribu-
tions are aligned well in the high expression levels.
However, at the lower end, there are dramatic differ-
ences between tissues. Heart has a number of genes
with significantly lower expression than both kidney and
liver, and liver has more low-expression genes than
kidney.
DNA methylation signature identifies tissue specificity
Figure 1D-E indicate variation in DNA methylation
between tissues. Nonetheless, it is not clear whether the
tissue-specific signatures can be identified from methyla-
tion data such that tissues can be classified based on
DNA methylation pattern. We investigated sample clas-
sification for DNA methylation data with three different
methods.
First, we performed hierarchical clustering using all
27,578 CpG markers. We tested different dissimilarity
measures, including Euclidean distance, Pearson’sd i s -
similarity and Spearman’s dissimilarity. Pearson’sa n d
Spearman’s dissimilarity are both based on data correla-
tion, thus, they have similar performance that is better
than Euclidean distance. For Illumina HumanMethyla-
tion27 data, most of genes have two or more CpG mar-
kers and the markers from the same genes should be
correlated. Thus, correlation based dissimilarity method
is more appropriate for this analysis. Ward linkage
method was used in hierarchical clustering. The result-
ing dendrogram was shown in Figure 2A. The 18
Figure 2 Sample clustering based on DNA methylation data.A .
A dendrogram of hierarchical clustering of 18 tissue samples using
all 27,578 DNA methylation markers. B. A heatmap of DNA
methylation data with 488 CpG markers that have the highest
standard deviation across all samples (sd > 0.2). Each row is a
sample, and each column is a marker. A dendrogram by hierarchical
clustering is given by hierarchical clustering. C. Methylation samples
are plotted on the second and third principal components. The
black circle points are liver samples, the red squares are kidney, and
the green triangles are heart.
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each representing a human tissue. Again, in terms of
DNA methylation, heart and kidney are closer to each
other than they are from liver. There was only one mis-
placement in this clustering, in that one kidney sample
was clustered into heart group though it also has short
distance to other kidney samples. Overall, tissue samples
were successfully clustered based on their DNA methy-
lation patterns.
Secondly, we looked for approaches to improve the
hierarchical clustering result. The misplacement
occurred in hierarchical clustering is likely due to the
large number of markers. The markers with low varia-
tion should not contribute to tissue classification, but
their variances may present as a noise to affect cluster-
ing. Therefore, we intended to filter out the markers
with low variance prior to clustering. We selected only
the CpG markers that have a standard deviation greater
than 0.2 and we obtained 488 markers. A heatmap is
shown in Figure 2B. Hierarchical clustering correctly
classified all 18 samples with their tissue labels. In Fig-
ure 2B, green is for low methylation levels and red is for
high levels. Most markers showed distinct methylation
levels among the three tissues, therefore, they can be
used as DNA signatures to represent different tissue.
Note that the methylation levels of the first 69 markers
in the heatmap are not aligned with tissue labels. We
found that 68 markers are located in X chromosome,
and they are methylation markers for sex imprinted
genes. Their high levels (red) indicate female, and low
levels (green) indicate male.
Thirdly, to further investigate methylation clustering,
we used an alternative method, principal components
analysis (PCA). One of the advantages of PCA is that it
disassociates the correlation between markers when
methylation data are transformed into principal compo-
nents. We plotted the 18 samples in the first three prin-
cipal components, and the samples are grouped into
their tissue labels with the second and third principal
components (Figure 2C). The circle points in black
color are for liver samples, the red squares are kidney
and the green triangles are heart. All points are grouped
well except one kidney sample that is close to heart
samples as in Figure 1A. However, from the dimension
of principal component 2, this kidney sample is still in
the range of other kidney samples rather than heart
samples.
Significantly expressed genes are affected by DNA
methylation
Next, we wanted to determine to what degree the gene
expression differences among tissues are affected by epi-
genetic changes. We used cuffdiff to find expression var-
iation (in FPKM) between tissues and then associated
the selected genes with their methylation levels in
HumanMethylation27 array. In total, we selected 1296
genes that were differentially expressed between any
pair of the three tissues and that exist in HumanMethy-
latin27 array. We further looked at whether these 1296
genes showed DNA methylation variation between tis-
sues as well. Unpaired t test was used to detect the
methylation differences among tissues and the results
are summarized in Figure 3. From the 1296 significantly
expressed genes, only about one third of them (483
genes) were not shown to have significant changes in
methylation between the three tissues. In total, 610
genes were shown to have significant methylation differ-
ence between heart and liver, 599 genes were significant
between kidney and liver, and 418 genes were significant
between heart and kidney. Among them, many genes
overlap to be significant in two or three tests. For exam-
ple, 340 genes showed significant results in comparing
both kidney and heart against liver, and 135 genes were
significant in all three tests, heart vs. kidney, heart vs.
liver, and kidney vs. liver. The list of these 135 genes is
shown in additional file 1. The distance of each CpG
markers to the transcriptional start site (TSS) was used
a covariate to fit into a linear model, but it was not
identified as a confounding factor to influence gene
e x p r e s s i o n .I ns h o r t ,t h em a jority of differentially
expressed genes showed significant changes in DNA
methylation, implying DNA methylation plays an impor-
tant role in mediating tissue differentiation.
We closely examined the 135 genes that not only have
significantly different level of mRNA expression, but
also have remarkably different DNA methylation
between any pair of the three tissues. We first studied
those genes that express very low in kidney, heart and
liver (FPKM <1). Their marginal expression may regu-
late important cellular and biochemical functions, but
this requires further elucidation, and and their expres-
sion should be more finely tuned. For instance, iodotyr-
osine deiodinase (IYD) was expressed at low levels in all
three tissues (0 in heart, 0.02 in kidney, and 0.26 in
liver), which was in accordance to its high methylation
level (0.81 in heart, 0.61 in kidney and 0.43 in kidney).
Its expression in heart and kidney is negligible, but it
has low expression in liver. This is consistent with the
lower level of DNA methylation in liver. Iodotyrosine
deiodinase, also known as iodotyrosine dehalogenase 1
especially expressed in the thyroid, and salvages iodide
by catalyzing deiodination of mono- and diiodotyrosine
during the biosynthesis of the thyroid hormone thyrox-
ine [24]. The function of IYD in liver remains unknown.
Next, we examined other genes that have distinct high
expressions in heart, kidney and liver (FPKM>1), which
includes 111 genes. This pool of genes may be critical
to the development and/or function of kidney, heart and
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tion. Transcobalamin I (TCN1) is a vitamin B12 binding
protein that regulates the absorption, trafficking and
secretion. TCN1 abnormality in the liver and kidney has
been thought to associate with impairment of these tis-
sues [25]. Its FPKM values were 0, 1.75 and 12.97 in
heart, kidney and liver respectively, corresponding to
beta values of 0.81, 0.59 and 0.73. Thus, its low expres-
sion in heart may be partially regulated by DNA methy-
lation. For another example, serine protease 23
(PRSS23), belongs to the peptidase S1 family [26], and is
highly expressed in kidney, heart and liver (117.69,
30.86 and 217.32 respectively), and this is consistent
with a negative regulatory role for DNA methylation in
controlling gene expression as all three tissues show
relatively low levels of DNA methylation (0.04 in kidney,
0.07 in heart and 0.06 in liver).
We next investigated whether DNA methylation is
associated with induced or repressed gene expression
during tissue differentiation. We selected the genes from
the 1296 genes that had sufficient changes in methyla-
tion levels between tissues (change of average beta
values greater than 0.3) and plotted the changes in
methylation and expression levels in Figure 4. The fold
change in expression levels was plotted on a logarithmic
scale. Although higher methylation levels are associated
with both lower and higher expression levels, Figure 4
shows a trend that high methylation is more likely to
repress gene expression. For example in Figure 4B of
kidney vs. heart, 10 genes show higher methylation
levels in kidney. Among the 10 genes, 8 show lower
expression levels, and only 2 show higher expression
levels in kidney than in heart. Therefore, the effect of
DNA methylation on gene expression may be bi-direc-
tional, nonetheless, higher methylation tends to repress
gene expression.
DNA methylation change correlates with gene expression
We further investigated whether the significant changes
in methylation will result in a measurable difference in
gene expression. To select the genes with significant
variation in methylation among the three tissues, we
performed analysis of variance (ANOVA) for each gene.
To adjust p values for multiple tests, we control false
discovery rate (FDR) at 5% and obtained 8687 CpG
markers that showed significant variation among the
three tissues. We then conducted regression analysis for
gene methylation levels and transcriptional levels. Simi-
larly, we adjusted p values by controlling FDR at 5%.
Amazingly, most of the 8687 CpG dinucleotides (5735)
showed significant correlation between methylation and
expression. The p value distribution of regression analy-
s i si ss h o w ni nF i g u r e5 A .I ti sc l e a rf r o mt h i sf i g u r e
that the amount of significant correlations is not
Figure 3 A Venn diagram of differentially expressed genes. Totally 1296 genes were differentially expressed between each pair of the three
tissues. The numbers of genes that have significant methylation difference between tissues are given in this Venn diagram.
Xie et al. BMC Systems Biology 2011, 5(Suppl 3):S4
http://www.biomedcentral.com/1752-0509/5/S3/S4
Page 6 of 11Figure 4 Expression fold change vs methylation change. The fold change of expression at natural log scale is used for y axis, and the delta
value is the difference in average beta values between two tissues. Only the 1296 differentially expressed genes with delta values greater than
0.3 are plotted. A. The pooled data of all pairs of tissue comparison. BCD. The data for comparison of two tissues.
Figure 5 The correlation of gene expression and DNA methylation. A. The distribution of p values for correlation of gene methylation and
expression. B. Histogram of Person’s correlation between gene methylation and expression for 5018 markers within CpG island sites. C.
Histogram of Person’s correlation between gene methylation and expression for 3669 markers outside CpG island sites.
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that DNA methylation extensively correlates with gene
expression during tissue differentiation.
From the 5735 CpG dinucleotides, 2960 were asso-
ciated with repressed gene expression, which was only
slightly larger than the number of genes (2775) whose
methylation levels were positively correlated gene
expression. This result further confirms our finding that
the effects of methylation on gene expression are bi-
directional during tissue differentiation. As Human-
Methylation27 markers are located either within or out-
side CpG island, we are interested to know if the
location of markers affects its regulation on expression.
Figure 5B-C show the distributions of Pearson’s correla-
tions for markers that are located within CpG island (B)
or outside of known CpG islands (C). The two distribu-
tions are similar with both peaks in positive and nega-
tive correlation regions. The peak in negative correlation
region is slightly higher than that in positive region, but
it is not significant. It indicates a weak trend of
increased methylation being associated with decreased
gene expression.
We identified several tissue specific genes by sorting
these genes whose methylation levels significantly corre-
lates with gene expression. We identified C4BPA,
expression of 0.03 in kidney, 0.04 in heart and 97.02 in
liver, associated with DNA methylation of 0.77, 0.80 and
0.33, respectively. C4BPA encodes Complement Compo-
nent 4 Binding Protein, which is known to be only pro-
duced in liver [27]. Other selected genes involving in
complement system include C5AR1, CD55, FGG, and
KRT1.A q u a p o r i n2( AQP2) was expressed high in the
kidney (15.84 in kidney, 0.17 in heart and 0.03 in liver)
with corresponding DNA methylation of 0.64 in kidney,
0.77 in heart and 0.87 in liver. We noticed that the
values of DNA methylation are relatively high in all
three tissues, while the value difference between kidney
and heart is 0.14 and that between kidney and liver is as
high as 0.24. AQP2, found in the apical cell membrane
and intracellular vesicles of the kidney’s collecting duct
principle cells, is an important vasopressin-regulated
water channel, which supports out finding of high corre-
lation between mRNA expression and DNA methylation
[28]. These results showed that integrative analysis of
genome wide DNA methylation and RNA-Seq transcrip-
tome data can reveal global regulation of gene expres-
sion by DNA methylation.
Discussion
Extensive chromatin remodelling occurs on a global
level during development. As embryonic stem (ES) cells
differentiate, they lose pluripotency [29,30]. Just as nor-
mal stem/progenitor cells are significantly remodelling
chromatin during differentiation, it is also important to
note that these cells also use DNA methylation, to colla-
borate with chromatin configuration, to stabilize key
gene expression patterns which emerge during normal
development and adult tissue cell turnover. For example,
localized DNA methylation changes occur at key cyto-
kine target genes during embryonic and adult differen-
tiation and maturation of lymphocytes [31]. We now
add data that methylation of CpG dinucleotides also
m a yp l a yak e yr o l ei nc o n t r o l l i n ge x p r e s s i o no fa
plethora of genes involved in directing tissue specificity
and diverse organ function. It is unclear, however, if this
methylation is the cause or simply a marker of gene
silencing, and further studies will be required to distin-
guish between these hypotheses.
The extent that adult tissue-specific stem/progenitor
cells retain this global permissive chromatin status is
likely tied to the extent with which they retain pluripo-
tency and little is known about DNA methylation differ-
ences between cell lineages. This study showed that not
only can tissue specific signatures be identified from glo-
bal DNA methylation patterns, but also the distance at
embryonic origin between tissues can be determined.
We found that heart and kidney are closer than heart
and liver as well as kidney and liver in the distance of
global DNA methylation, reflecting heart and kidney has
the same embryonic origin, mesoderm, whereas liver
develops from endoderm. This finding might be utilized
to trace the origin of cell lineage and discover the rela-
tionship between cell lineages.
In global genomic packaging, for all types of cells,
DNA methylation may be a key component of repressive
chromatin which functions to give long-term silencing
of transposons, stabilization of silenced genes in the
processes of imprinting and x-inactivation [17]. Mam-
malian females use x-chromosome inactivation to equal-
ize the imbalance of X-chromosome gene expression
created by females having two X chromosomes in con-
trast to the male XY. Dense regions of CpG dinucleo-
tides, termed CpG islands, along the entire X
chromosome are also DNA hypermethylated in the
embryo [32]. Out of 466 CpG markers that have the
highest variability between heart, kidney and liver, 69
markers are located in X chromosome and were highly
methylated only in female tissues. All these 69 markers
except one are located in CpG islands. The marker that
is not in a CpG island is for MSN gene that encodes
moesin. Interestingly, even including these X chromo-
some inactivation genes, the 466 markers still correctly
clustered all tissue samples.
Promoter hypermethylation has been mainly asso-
ciated with gene silencing [33]. However, in this study
we found that DNA methylation was either positively or
negatively correlated with gene expression. Because the
majority of genes that have methylation variation
Xie et al. BMC Systems Biology 2011, 5(Suppl 3):S4
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and transcriptional levels, such number of correlations
was so significant that it could not be generated by
chance. The number of negative correlations was only
slightly larger than that of positive correlations and this
difference was not significant. This result suggests two
possibilities, either DNA methylation is bi-directional in
regulating gene expression or there is a multiple-factor
complicated system that monitors gene expression dur-
ing tissue differentiation. The location of CpG markers
has been reported to be a factor to influence the effect
of methylation on gene regulation [13]. We have tested
locations, such as the distance to transcriptional start
s i t e( T S S )o rw h e t h e ri n s i d eo ro u t s i d eaC p Gi s l a n d ,
a n df a i l e dt of i n dt h e ya f f e c to nt h ec o r r e l a t i o n so f
methylation and gene expression. This result need to be
further investigated with denser methylation arrays, such
as Illumina Infinium 450 K.
Aberrant DNA methylation is also a hallmark of most
cancers and the changes begin in the earliest pre-malig-
nant and hyperplastic lesions, and throughout tumor pro-
gression, and contributes significantly to the biology of
cancer [33-36], but the role of epigenetic/epigenomic
changes in other diseases remains an area of active focus
of many researchers. In order properly understand the
consequence of DNA methylation changes in various
human disease states, we need to understand the epige-
netic code of normal cells and the role that DNA methyla-
tion places in directing tissue specificity. Furthermore, as
many disease states such as cancer may present cells with
altered differentiation patterns (i.e. evidence for stem cells
in cancer) or characteristics of mixed lineages (epithelial
to mesenchymal transition) we need to understand the
patterns of DNA methylation between different types of
normal cells in order to properly gauge the significance of
any aberrant findings. We believe that this study will help
underscore the importance of methylation changes at
CpG dinucleotides in the promoter regions of genes, and
serve as a baseline to measure abnormal methylation
changes associated with pathological conditions.
Conclusions
We studied global DNA methylation in three human tis-
sues, heart, kidney and liver, and found that tissues have
distinct DNA methylation patterns. It underlines the
existence of tissue-specific methylation signatures and
implies an important role played by DNA methylation
in mediating normal tissue differentiation. By joining
w i t ht r a n s c r i p t o m ed a t am e a s u r e db yR N A - S e q ,w e
were able to correlate most methylation variation
between tissues with gene expression levels. It indicates
that DNA methylation influences normal tissue differen-
tiation via regulating gene expression. Further studies
need to be carried out to verify our findings in other
normal tissues and to investigate the genes and path-
ways that are involved in this biological process.
Methods
DNA methylation quantification
For each sample, DNA methylation level at each CpG
site was given in percentage by
β =
M
M + U
· 100%,
Where M is the signal strength of methylated CpG
given by Illumina HumanMethylation27 array, and U is
the signal strength of unmethylated CpG. To ensuring
consistent quality between samples, we plotted the beta
values between each pair of samples from the same tis-
sues, and the average beta values between each pair of
tissues. For each marker, the difference in beta values
between tissues was tested with unpaired t test.
ANOVA was used to assess the methylation variation
among the three tissues.
RNA-Seq data quantification
The 50 bp paired-end RNA-Seq short reads from Illu-
mina HiSeq 2000 were firstly mapped onto the reference
sequences of human genome 19 using Tophat. The
reference sequence was downloaded from the genome
browser website of the University of California at Santa
Cruz on April 13, 2011. The mapped short reads were
further processed to assemble transcripts and quantify
transcriptional levels using Cufflinks. Transcriptional
levels were quantified as Fragments Per Kilobase of
exon per Million fragments mapped (FPKM). FPKM
values were logarithm transformed for further analysis
because the distribution of transcriptional levels skews
right. Quantile-quantile plot (QQ plot) between tissues
were drawn by R statistical programming language. The
significantly differently expressed genes were identified
cuffdiff tool within Cufflinks package.
DNA methylation sample clustering
All 18 samples from 3 human tissues were clustered
using hierarchical clustering method. All 27,578 CpG
markers were used for clustering. Different dissimilarity
and linkage methods were tested and evaluated. The
clustering dendrogram was drawn using Pearson’sd i s -
similarity and Ward linkage method.
In order to plot the methylation data in a heatmap, we
selected 488 markers whose standard deviation of
methylation levels across all18 samples were greater
than 0.2. Heatmap of all samples was drawn with sam-
ples in rows and markers in column. Hierarchical clus-
tering was used to group samples (rows) using Pearson’s
dissimilarity and Ward linkage.
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tigate the relationship between samples. Singular vector
decomposition was used to transform all 27,578 markers
into 18 principal components (18 is the number of sam-
ples). The samples were plotted on first few principal
components for clustering.
Integrative analysis of DNA methylation and gene
expression
Genes that were expressed differentially between any
pair of tissues were selected by cuffdiff, a tool package
within Cufflinks. In order to find whether these genes
had methylation variation as well, we performed t tests
for beta values between each pair of tissues, and per-
formed ANOVA to compare beta values among all
three tissues. The numbers of genes that show signifi-
cant differences between tissues both in transcriptional
and methylation levels were counted. The distance of
CpG markers to TSS was used as a covariate factor for
a regression analysis to test if it was a confounding fac-
tor in this analysis.
To detect the correlation between DNA methylation
and gene expression, we performed ANOVA to select
the CpG markers that showed methylation variation
among the three tissues. Regression analysis followed to
test whether the changes in methylation were correlated
with gene expression. All tests were controlled by FDR
to adjust for multiple tests. The distribution of p values
of regression analysis was drawn to check whether the
distribution as uniform. CpG markers were then
grouped into their locations, inside or outside CpG
islands, and the effects of location on the distribution of
Pearson’s correlation was tested.
All data processing and analyses were conducted in a
Dell PowerEdge R910 worktation.
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